Home>>Signaling Pathways>> Chromatin/Epigenetics>> HDAC>>BRD73954

BRD73954

Catalog No.GC12484

potent and selective HDAC inhibitor

Products are for research use only. Not for human use. We do not sell to patients.

BRD73954 Chemical Structure

Cas No.: 1440209-96-0

Size Price Stock Qty
5mg
$72.00
In stock
25mg
$243.00
In stock
100mg
$481.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

BRD73954 is a potent and selective inhibitor of HDAC with IC50 values of 36 and 120 nM for HDAC6 and HDAC8, respectively [1].

Histone deacetylases (HADCs) are a series of enzymes that remove acetyl groups from an ε-N-acetyl lysine amino acid on a histone and make the histones to wrap the DNA more tightly, which prevent transcription [1].

BRD73954 is a potent and selective HDAC inhibitor with IC50 values of 36 and 120 nM for HDAC6 and HDAC8, respectively. Also, BRD73954 inhibited HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC7 and HDAC9 with IC50 values of 12, 9.0, 23, >33, >33, 13 and >33 μM, respectively. In HeLa cells, BRD73954 significantly increased α-tubulin acetylation, which was a substrate for HDAC6, while there was no change in the acetylation state of histone H3, which was a substrate for HDACs 1, 2 and 3 [1].

Reference:
[1].  Olson DE, Wagner FF, Kaya T, et al. Discovery of the first histone deacetylase 6/8 dual inhibitors. J Med Chem, 2013, 56(11): 4816-4820.

Reviews

Review for BRD73954

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for BRD73954

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.